Sign Out
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women, denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures.
Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see Pharmacology: Pharmacodynamics under Actions). In men with prostate cancer receiving hormone ablation, Resyniv significantly reduces the risk of vertebral fractures.
Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see Pharmacology: Pharmacodynamics under Actions).
Continue with Google